ELAN logo

ELAN Stock

Profile

Full Name:

Elanco Animal Health Incorporated

Sector:

Healthcare

Country:

United States

IPO:

20 September 2018

Indexes:

Not included

Description:

Elanco Animal Health Incorporated is a pharmaceutical company that develops and markets products for the treatment of animals. The Prevention of diseases in domestic animals segment includes a wide range of parasiticides. The Therapy for domestic animals segment provides means and services for pain and osteoarthritis treatment, with different modes of action, indications, and disease stages. The Protein and Health segment includes vaccines, food enzymes, and antibiotics for animals. The Ruminant and Swine category segment is engaged in the development of vaccines, antibiotics, implants, parasiticides, and animal origin products widely used in the breeding of ruminant animals. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

Key Details

Price

$12.28

Annual Revenue

$4.42 B(+0.14% YoY)

Annual EPS

-$2.50(-1462.50% YoY)

Annual ROE

-18.22%

Beta

0.99

Events Calendar

Earnings

Next earnings date:

Feb 26, 2025

Recent quarterly earnings:

Nov 07, 2024

Recent annual earnings:

Feb 26, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

29 Jan '25 Morgan Stanley
Equal-Weight
07 Jan '25 Stifel
Buy
09 Dec '24 UBS
Buy
02 Dec '24 Leerink Partners
Market Perform
08 Nov '24 Barclays
Overweight
28 Oct '24 Barclays
Overweight
23 Sept '24 Barclays
Overweight
19 Sept '24 Stifel
Buy
19 Sept '24 Morgan Stanley
Equal-Weight
01 July '24 Piper Sandler
Neutral

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Shareholders to Inquire about Securities Investigation
ELAN
accessnewswire.com29 January 2025

NEW YORK CITY, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC is looking into possible claims for those who bought shares of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who acquired Elanco securities before November 7, 2023, and still own them, are invited to find more details and help with the investigation by visiting the firm's website: bgandg.com/ELAN.

Meet the Faces of Zen: Elanco's Zenrelia™ (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal
Meet the Faces of Zen: Elanco's Zenrelia™ (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal
Meet the Faces of Zen: Elanco's Zenrelia™ (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal
ELAN
prnewswire.com27 January 2025

Hunter, Trooper, Scrappy, and Buckaroo discover peace through Zenrelia. A new study published in the respected journal Veterinary Dermatology examines the results of using Zenrelia compared to Apoquel® (oclacitinib tablet). The study focuses on issues like scratching, rubbing, chewing, and licking.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Connect
ELAN
accessnewswire.com26 January 2025

NEW YORK CITY, NY / ACCESS Newswire / January 26, 2025 / Bronstein, Gewirtz & Grossman, LLC is looking into possible claims for those who bought shares of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who acquired Elanco securities before November 7, 2023, and still own them, are invited to find more details and help with the investigation by visiting the firm's website: bgandg.com/ELAN.

Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
ELAN
accesswire.com15 January 2025

Bronstein, Gewirtz & Grossman, LLC is looking into possible claims for those who bought shares of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). If you purchased Elanco securities before November 7, 2023, and still own them, you are invited to find out more and help with the investigation by visiting the firm's website: bgandg.com/ELAN.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect
ELAN
accesswire.com12 January 2025

NEW YORK CITY, NY / ACCESSWIRE / January 12, 2025 / Bronstein, Gewirtz & Grossman, LLC is looking into possible claims for those who bought shares of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who acquired Elanco securities before November 7, 2023, and still own them, are invited to find more details and help with the investigation by visiting the firm's website: bgandg.com/ELAN.

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation
ELAN
accesswire.com05 January 2025

NEW YORK CITY, NY / ACCESSWIRE / January 5, 2025 / Bronstein, Gewirtz & Grossman, LLC is looking into possible claims for those who bought shares of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). Investors who acquired Elanco securities before November 7, 2023, and still own them, are invited to find more details and help with the investigation by visiting the firm's website: bgandg.com/ELAN.

Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Investors to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Investors to Inquire about Securities Investigation
ELAN
accesswire.com29 December 2024

Bronstein, Gewirtz & Grossman, LLC is looking into possible claims for those who bought shares of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). If you purchased Elanco securities before November 7, 2023, and still own them, you are invited to find out more and help with the investigation by visiting the firm's website: bgandg.com/ELAN.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Reach Out
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Reach Out
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Reach Out
ELAN
accesswire.com26 December 2024

Bronstein, Gewirtz & Grossman, LLC is looking into possible claims for those who bought shares of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). If you purchased Elanco securities before November 7, 2023, and still own them, you are invited to find out more and help with the investigation by visiting the firm's website: bgandg.com/ELAN.

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Reach Out
ELAN
accesswire.com22 December 2024

Bronstein, Gewirtz & Grossman, LLC is looking into possible claims for those who bought shares of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). If you purchased Elanco securities before November 7, 2023, and still own them, you are invited to find out more and help with the investigation by visiting the firm's website: bgandg.com/ELAN.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Connect
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Connect
ELAN
accesswire.com18 December 2024

Bronstein, Gewirtz & Grossman, LLC is looking into possible claims for those who bought shares of Elanco Animal Health Incorporated ("Elanco" or "the Company") (NYSE:ELAN). If you purchased Elanco securities before November 7, 2023, and still own them, you are invited to find out more and help with the investigation by visiting the firm's website: bgandg.com/ELAN.

FAQ

  • What is the primary business of Elanco Animal Health Incorporated?
  • What is the ticker symbol for Elanco Animal Health Incorporated?
  • Does Elanco Animal Health Incorporated pay dividends?
  • What sector is Elanco Animal Health Incorporated in?
  • What industry is Elanco Animal Health Incorporated in?
  • What country is Elanco Animal Health Incorporated based in?
  • When did Elanco Animal Health Incorporated go public?
  • Is Elanco Animal Health Incorporated in the S&P 500?
  • Is Elanco Animal Health Incorporated in the NASDAQ 100?
  • Is Elanco Animal Health Incorporated in the Dow Jones?
  • When was Elanco Animal Health Incorporated's last earnings report?
  • When does Elanco Animal Health Incorporated report earnings?
  • Should I buy Elanco Animal Health Incorporated stock now?

What is the primary business of Elanco Animal Health Incorporated?

Elanco Animal Health Incorporated is a pharmaceutical company that develops and markets products for the treatment of animals. The Prevention of diseases in domestic animals segment includes a wide range of parasiticides. The Therapy for domestic animals segment provides means and services for pain and osteoarthritis treatment, with different modes of action, indications, and disease stages. The Protein and Health segment includes vaccines, food enzymes, and antibiotics for animals. The Ruminant and Swine category segment is engaged in the development of vaccines, antibiotics, implants, parasiticides, and animal origin products widely used in the breeding of ruminant animals. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.

What is the ticker symbol for Elanco Animal Health Incorporated?

The ticker symbol for Elanco Animal Health Incorporated is NYSE:ELAN

Does Elanco Animal Health Incorporated pay dividends?

No, Elanco Animal Health Incorporated does not pay dividends

What sector is Elanco Animal Health Incorporated in?

Elanco Animal Health Incorporated is in the Healthcare sector

What industry is Elanco Animal Health Incorporated in?

Elanco Animal Health Incorporated is in the Drug Manufacturers - Specialty & Generic industry

What country is Elanco Animal Health Incorporated based in?

Elanco Animal Health Incorporated is headquartered in United States

When did Elanco Animal Health Incorporated go public?

Elanco Animal Health Incorporated's initial public offering (IPO) was on 20 September 2018

Is Elanco Animal Health Incorporated in the S&P 500?

No, Elanco Animal Health Incorporated is not included in the S&P 500 index

Is Elanco Animal Health Incorporated in the NASDAQ 100?

No, Elanco Animal Health Incorporated is not included in the NASDAQ 100 index

Is Elanco Animal Health Incorporated in the Dow Jones?

No, Elanco Animal Health Incorporated is not included in the Dow Jones index

When was Elanco Animal Health Incorporated's last earnings report?

Elanco Animal Health Incorporated's most recent earnings report was on 7 November 2024

When does Elanco Animal Health Incorporated report earnings?

The next expected earnings date for Elanco Animal Health Incorporated is 26 February 2025

Should I buy Elanco Animal Health Incorporated stock now?

As of today, analysts generally recommend a 'Buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions